BGMS
NASDAQ · Biotechnology
Bio Green Med Solution Inc
$0.90
-0.02 (-1.79%)
BGMS News30 articles
Bio Green Med Stock Surges 170% Pre-Market on All-Stock Future NRG Deal, Massive Dilution Ahead
Bio Green Med shares soared nearly 170% pre-market on an all-stock deal to buy Future NRG, but existing holders will own under 1% of the combined firm, raising dilution concerns.
Twist Bioscience Surges 11% on Lilly TuneLab Pact, Yet Financial Terms Remain Vague
Twist Bioscience shares rose 10.8% following a partnership with Eli Lilly's TuneLab, but the lack of disclosed financial terms leaves the deal's revenue impact uncertain.
Biodexa Shares Surge Premarket, But Funding Questions Loom
Biodexa Pharmaceuticals' shares jumped ~85% premarket, but a funding gap looms for Q4. The company's Serenta trial enrollment is past halfway, offering a positive counterweight.
PDS Biotech Surges 60% Despite Heavy Dilution from $11.3M Financing
PDSB shares surged 60% after a $11.3M PIPE financing, but the deal adds 40M share equivalents, diluting existing holders by over 70%.
Anthropic's Dual-Use Biology Cases Spotlight Access Control as AI Valuation Soars
Anthropic disclosed five dual-use biology cases, highlighting access-control challenges. The company's $965B valuation and cloud partnerships with Amazon and Alphabet hinge on balancing safety with commercial utility.
Biodexa Soars 97% but Funding Crunch Looms in Q4
BDRX surged 97% to $1.30, but Biodexa warns of another financing in Q4. Enrollment in its Phase 3 trial is ahead of schedule, yet the cash runway remains tight.
PDS Biotech Soars 36% on $22.55M Financing: Dilution Concerns Loom
PDS Biotechnology (PDSB) surged 36% after announcing a $22.55 million PIPE led by Nant Capital, but the deal involves significant dilution. Here's the breakdown.
PDS Biotech Diverts All New Equity Cash to Lender Amid Funding Crunch
PDS Biotech's lender now takes 100% of net cash from new equity deals outside its ATM until a $6M promissory note is repaid, worsening an already tight funding situation.
BioXcel Surges 8% as 143M Shares Trade Ahead of Nasdaq Delisting
BioXcel shares jumped 8% with 143M shares traded ahead of Nasdaq delisting. The surge reflects distressed asset trading as Teva's $57.5M bid moves forward.
bioAffinity Soars 45% on CyPath Surveillance Potential
bioAffinity shares jumped 45% after proposing CyPath Lung for cancer surveillance, with volume 56x shares outstanding.
BioXcel Plunges 75% as Teva Stalking-Horse Bid and Chapter 11 Filing Shake Investors
BioXcel shares collapsed 74.8% after bankruptcy filing; Teva offers $57.5M for assets, but equity holders face near-total loss.
Xtant Medical Jumps 16% on BioHorizons Dental Distribution Pact
Xtant Medical shares soared 16% after BioHorizons secured exclusive rights to distribute its Prolifica dental product line, expanding market access.
BioNTech Slumps 6.6% as Colorectal Cancer Vaccine Trial Halted
BioNTech shares dropped 6.6% after the company ended a Phase 2 trial of its colorectal cancer vaccine. The decision follows a data safety board recommendation and erases about $1.8 billion in market value.
BioLineRx Plunges 20% on Dilutive $3.75M Offering
BioLineRx shares dropped 20% after a $3.75M offering priced at $2.78 per ADS, with warrants that could significantly increase dilution.
Propanc Biopharma Plunges 19% Premarket After 108% Surge on PRP Data
Propanc Biopharma (PPCB) shares dropped 19.3% premarket to $1.80 after a 108% surge on PRP data. Despite strong animal results, revenue and cash concerns persist.
BioXcel Therapeutics Files Chapter 11; Shares Plunge 62%
BioXcel Therapeutics (BTAI) filed for Chapter 11 bankruptcy, sending shares down 62.4% to $0.27. The company's liabilities ($100M-$500M) far exceed its assets ($10M-$50M), leaving common equity subordinate.
Biohaven Shares Slide 5% as Raymond James Slashes Target on Opakalim Deal
Biohaven (BHVN) shares dropped 4.9% to $16.12 after Raymond James cut its price target to $30 from $50, citing the opakalim licensing deal that brings $400M cash but reduces upside.
Propanc Biopharma Rockets 151% on Promising PRP Pancreatic Cancer Data
Propanc Biopharma (PPCB) shares jumped 151% after PRP reduced tumor growth by over 90% in pancreatic cancer models, with volume nearly 20 times normal.
Biohaven Shares Slide 7% as Investors Reassess Opakalim Deal Value
Biohaven shares fell 7.1% to $15.75, reversing nearly half of Wednesday's gains from its $400 million opakalim licensing agreement with SK Biopharmaceuticals.
Generate Biomedicines Plunges 20% as Lock-Up Expiry Floods Market
Generate Biomedicines (GENB) shares fell 20% as a 103.14 million-share lock-up expired, quadrupling the tradable float and heightening supply worries.
Biohaven Stock Soars 25% on Trade Secret Ruling
Biohaven shares surged 25% after a federal court finalized a $4 million trade secret ruling, boosting market cap by $553 million as investors bet on platform value.
Generate Biomedicines Surges 12% Ahead of Lockup Expiry
Generate Biomedicines (GENB) shares jumped 12.3% ahead of the expiration of a 103.14 million-share lockup, with trading volume nearly four times the average.
Alamar Biosciences Stock Jumps 31% on Strong Consumables Growth
Alamar Biosciences (ALMR) shares soared 31% after Q2 revenue surged 82%, fueled by consumables sales that lifted gross margins and strengthened the recurring revenue outlook.
Ensysce Biosciences Stock Jumps 48% Premarket, Nasdaq Compliance Still Elusive
Ensysce Biosciences (NASDAQ:ENSC) shares jumped 48% in premarket trading, yet the stock remains 141% below the $1 minimum bid price required by Nasdaq. The compliance window begins August 11.
Gossamer Bio Surges on FDA Filing Update; Cash Covenant Looms
Gossamer Bio shares surged 46% on FDA feedback supporting its seralutinib NDA filing. Cash covenant and dilution risks persist.
Gossamer Bio Stock Jumps on FDA Filing Update, but Cash and Dilution Risks Remain
Gossamer Bio shares surged after an FDA filing update, but cash concerns and potential dilution continue to weigh on the stock.
Danaher's 50% Rebound Faces $100M Bioprocessing Deferral Hurdle
Danaher shares rebounded 50% from a post-earnings drop, but a $100 million bioprocessing revenue delay to 2027 tests the recovery.
Advanced Biomed Surges 74.6% After Terminating $25M Equity Facility
Shares of Advanced Biomed (ADVB) jumped 74.6% after the company terminated a $25 million equity facility, removing overhang of potential dilution.
Danaher Plunges 11% as Biotech Growth Disappoints, Triggering Valuation Reset
Danaher shares dropped 11% after its biotech segment underperformed expectations, leading to a valuation adjustment. Full-year core growth guidance was narrowed to 3%-4%.
Danaher Tumbles 11% as Biotech Growth Disappoints, Triggering Valuation Reset
Danaher shares plunged 11% on Tuesday after biotech growth fell short of expectations, prompting a sharp valuation reset even as quarterly revenue and earnings topped forecasts.